^
    Apply
    A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) (NCT04819100)
    Phase 3
    Eli Lilly and Company
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/20/2021
    Primary completion :
    05/01/2027
    Completion :
    08/01/2032
    RET
    |
    RET fusion
    |
    Retevmo (selpercatinib)
    Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors (NCT04669496)
    Phase 2/3
    Shanghai Zhongshan Hospital
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/20/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    TMB • MSI • CEACAM5 • MUC16
    |
    PD-L1 expression
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin
    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) (NCT03829319)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    03/25/2019
    Primary completion :
    08/11/2023
    Completion :
    08/30/2024
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed
    Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities ((MARGARET)) (NCT04683250)
    Phase 1/2
    Taiho Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/16/2020
    Primary completion :
    03/01/2030
    Completion :
    03/01/2031
    RET
    |
    RET fusion
    |
    vepafestinib (TAS0953/HM06)
    Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) (NCT03829332)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    03/13/2019
    Primary completion :
    05/19/2021
    Completion :
    04/24/2024
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (LITESPARK-016) (NCT04976634)
    Phase 2
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    08/18/2021
    Primary completion :
    03/22/2027
    Completion :
    03/22/2027
    MSI
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)
    Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma (NCT05823311)
    Phase 3
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    09/01/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    PD-L1
    |
    cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma (NCT05532059)
    Phase 2
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/31/2022
    Primary completion :
    08/31/2025
    Completion :
    08/31/2028
    PD-L1
    |
    cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321) (NCT04280081)
    Phase 2
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    03/16/2020
    Primary completion :
    03/25/2021
    Completion :
    11/01/2027
    RET
    |
    RET mutation
    |
    Retevmo (selpercatinib)
    A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET Lung) (NCT04222972)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    07/24/2020
    Primary completion :
    01/27/2025
    Completion :
    01/27/2025
    RET
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)
    Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (NCT04662710)
    Phase 3
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/30/2020
    Primary completion :
    10/29/2024
    Completion :
    03/31/2026
    PD-L1
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • oxaliplatin • leucovorin calcium • levoleucovorin calcium
    Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer (NCT04759911)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/26/2021
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    RET
    |
    Retevmo (selpercatinib)
    A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) (NCT04211337)
    Phase 3
    Loxo Oncology, Inc.
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/11/2020
    Primary completion :
    05/22/2023
    Completion :
    02/01/2026
    RET
    |
    RET mutation
    |
    Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)
    Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (NCT05114421)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    11/09/2021
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    CD4
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) (NCT04194944)
    Phase 3
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    02/17/2020
    Primary completion :
    05/01/2023
    Completion :
    06/01/2026
    RET
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Retevmo (selpercatinib) • pemetrexed
    A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs (PELICAN) (NCT06232564)
    Phase 2
    Imperial College London
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    07/08/2024
    Primary completion :
    03/02/2028
    Completion :
    08/02/2028
    PD-1 • VEGFA • CD34 • FOXP3
    |
    Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV
    A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma (NCT05147558)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    01/27/2025
    Initiation :
    12/23/2021
    Primary completion :
    12/23/2025
    Completion :
    12/23/2025
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma (NCT04955743)
    Phase 2
    Yale University
    Recruiting
    Last update posted :
    12/24/2024
    Initiation :
    02/09/2022
    Primary completion :
    01/31/2027
    Completion :
    01/31/2027
    BRAF
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) (NCT03820986)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    12/02/2024
    Initiation :
    03/12/2019
    Primary completion :
    01/18/2023
    Completion :
    11/01/2024
    BRAF
    |
    BRAF mutation • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study (LEAP-003 China Extension) (NCT04889118)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    12/02/2024
    Initiation :
    07/14/2020
    Primary completion :
    01/18/2023
    Completion :
    11/01/2024
    BRAF
    |
    BRAF mutation • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) (NCT04267120)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    11/26/2024
    Initiation :
    07/29/2020
    Primary completion :
    07/09/2024
    Completion :
    12/31/2025
    SDHB • TSC1
    |
    TSC1 deletion
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC (AMBER) (NCT06068153)
    Phase 2
    ETOP IBCSG Partners Foundation
    Withdrawn
    Last update posted :
    11/20/2024
    Initiation :
    03/01/2025
    Primary completion :
    09/30/2026
    Completion :
    12/30/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lenvima (lenvatinib) • Lumakras (sotorasib)
    A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer (NCT06110793)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    11/18/2024
    Initiation :
    12/29/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    HER-2
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • fulvestrant
    Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) (NCT03976375)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    11/18/2024
    Initiation :
    06/26/2019
    Primary completion :
    08/11/2023
    Completion :
    08/22/2024
    EGFR • KRAS • ALK • ROS1
    |
    KRAS mutation • EGFR L858R • ALK rearrangement • RAS mutation
    |
    Keytruda (pembrolizumab) • docetaxel • Lenvima (lenvatinib)
    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (NCT03797326)
    Phase 2
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    11/15/2024
    Initiation :
    02/12/2019
    Primary completion :
    10/28/2024
    Completion :
    10/28/2024
    HER-2 • PD-L1 • ER • PGR
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA) (NCT04287829)
    Phase 2
    The Netherlands Cancer Institute
    Active, not recruiting
    Last update posted :
    11/05/2024
    Initiation :
    03/01/2021
    Primary completion :
    12/05/2024
    Completion :
    03/05/2026
    TMB • CTLA4
    |
    Keytruda (pembrolizumab) • cisplatin • Lenvima (lenvatinib)
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (NCT04776148)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    10/29/2024
    Initiation :
    03/29/2021
    Primary completion :
    02/20/2023
    Completion :
    09/27/2024
    EGFR • KRAS • BRAF • MSI
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study (LEAP-006 China Extension) (NCT04716933)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    10/04/2024
    Initiation :
    11/05/2019
    Primary completion :
    08/11/2023
    Completion :
    08/30/2024
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed
    Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (NCT03173560)
    Phase 2
    Eisai Inc.
    Completed
    Last update posted :
    09/19/2024
    Initiation :
    08/17/2017
    Primary completion :
    02/14/2020
    Completion :
    06/30/2024
    PD-L1 • PD-1
    |
    everolimus • Lenvima (lenvatinib)
    Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC) (NCT04848337)
    Phase 2
    University of Michigan Rogel Cancer Center
    Recruiting
    Last update posted :
    08/14/2024
    Initiation :
    05/25/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    SYP • CHGA
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI) (NCT04710628)
    Phase 2
    MedSIR
    Active, not recruiting
    Last update posted :
    08/08/2024
    Initiation :
    09/21/2021
    Primary completion :
    07/01/2024
    Completion :
    01/31/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative (LENVABLA) (NCT05113186)
    Phase 2
    Assistance Publique - Hôpitaux de Paris
    Active, not recruiting
    Last update posted :
    08/01/2024
    Initiation :
    02/02/2022
    Primary completion :
    07/02/2025
    Completion :
    10/02/2026
    AFP • FLT4 • VEGFC
    |
    Lenvima (lenvatinib)
    Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study (LEAP-007 China Extension) (NCT04676412)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/01/2024
    Initiation :
    10/23/2019
    Primary completion :
    05/19/2021
    Completion :
    03/29/2024
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) (NCT03898180)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    07/22/2024
    Initiation :
    05/06/2019
    Primary completion :
    07/26/2021
    Completion :
    05/20/2024
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • Lenvima (lenvatinib)
    Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (NCT02973997)
    Phase 2
    Academic and Community Cancer Research United
    Completed
    Last update posted :
    07/01/2024
    Initiation :
    02/07/2018
    Primary completion :
    08/15/2022
    Completion :
    10/08/2023
    CD8 • PD-L2
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM) (NCT05545969)
    Phase 2
    Melanoma Institute Australia
    Withdrawn
    Last update posted :
    06/26/2024
    Initiation :
    03/01/2024
    Primary completion :
    05/01/2026
    Completion :
    05/01/2036
    HIF1A
    |
    HIF1A expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (NCT06253494)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/14/2024
    Initiation :
    05/14/2024
    Primary completion :
    12/31/2026
    Completion :
    12/31/2028
    HER-2
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Anktiva (nogapendekin alfa inbakicept-pmln)
    Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) (NCT06458036)
    Phase 2
    Children's Hospital of Philadelphia
    Not yet recruiting
    Last update posted :
    06/13/2024
    Initiation :
    08/01/2024
    Primary completion :
    08/01/2030
    Completion :
    08/01/2031
    RET
    |
    Retevmo (selpercatinib)
    Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer (Lung-MAP Sub-Study) (NCT05364645)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/25/2022
    Primary completion :
    06/27/2023
    Completion :
    05/01/2029
    EGFR • KRAS • BRAF • ALK • MET • RET • ROS1
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive
    |
    carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)
    Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (LUNG-MAP Sub-Study) (NCT04268550)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/08/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    EGFR • KRAS • BRAF • ALK • MET • RET • ROS1
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive
    |
    Retevmo (selpercatinib)
    Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor (NCT05181033)
    Phase 2
    National University Hospital, Singapore
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    12/27/2021
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    ER
    |
    ER positive
    |
    Lenvima (lenvatinib) • fulvestrant • letrozole
    Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC (NCT05433116)
    Phase 2
    Universität des Saarlandes
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/25/2023
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    PD-L1
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)